Various immunostimulants, such as Toll-like receptor (TLR) agonists and stimulator of interferon genes (STING) agonists, have been preclinically or clinically tested for in situ tumor vaccination, but render suboptimal therapeutic efficacy due to poor tumor retention and rapid systemic dissemination [982]. Here, STING1 is linked to neoplasm.